Medical treatment of hyperprolactinaemic disorders.
The current status of treatments designed to treat prolactinoma and other hyperprolactinaemic disorders is reviewed. The use of ergoline derivatives is described to correct prolactin levels, restore reproductive dysfunctions and reduce the size of prolactinomas. Side effects are minimal but withdrawal is almost always followed by a recurrence of the original condition. Radiation therapy is less effective and surgical resection of prolactinomas is effective, but the condition may recur. The authors recommend that dopaminergic drugs should be the primary therapies for prolactin-secreting adenomas and idiopathic hyperprolactinaemia, and surgery should be reserved for dopamine-resistant conditions.
D000172:Acromegaly / Q000150:complications; D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004298:Dopamine; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D008090:Lisuride / Q000627:therapeutic use; D010479:Pergolide / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D011605:Psychoses, Substance-Induced; D013629:Tamoxifen / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D004873:Ergolines; D013629:Tamoxifen; D010479:Pergolide; D001971:Bromocriptine; D011388:Prolactin; D008090:Lisuride; C031649:mesulergine; D004298:Dopamine